Blood and Marrow Transplant (BMT), Myelodysplastic Syndromes, Myelodysplastic Syndromes (MDS), Myeloproliferative Disorders, Myeloproliferative Disorders (MPD)
Conditions
Brief summary
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.
Detailed description
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
Interventions
PROCEDUREnonmyeloablative allogeneic hematopoietic cell transplant
Sponsors
National Institutes of Health (NIH)
Stanford University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
- Myelodysplastic Syndromes * Myeloproliferative Disorders * HLA matched donor available
Exclusion criteria
- organ dysfunction * HIV positive
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of transplant | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| safety profile of nonmyeloablative transplant, graft versus host disease, graft rejection, non-relapse mortality, use of donor lymphocyte infusion | 1 year |
Countries
United States
Outcome results
None listed